Ulrich Jager

Ulrich Jager

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 199 publications

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Journal: Blood
Published: April 01, 2026

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

Journal: American journal of hematology
Published: January 30, 2026

DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia.

DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia.

Journal: Blood advances
Published: November 12, 2025

DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia.

DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia.

Journal: Blood advances
Published: November 12, 2025

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.

Journal: Blood advances
Published: May 06, 2025

The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies.

The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies.

Journal: HemaSphere
Published: April 29, 2025

Comparing functional and genomic-based precision medicine in blood cancer patients.

Comparing functional and genomic-based precision medicine in blood cancer patients.

Journal: HemaSphere
Published: February 20, 2025

Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.

Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.

Journal: Blood advances
Published: November 18, 2024

Somatic Recombination Between an Ancient and a Recent NOTCH2 Gene Variant Is Associated with the NOTCH2 Gain-of-Function Phenotype in Chronic Lymphocytic Leukemia.

Somatic Recombination Between an Ancient and a Recent NOTCH2 Gene Variant Is Associated with the NOTCH2 Gain-of-Function Phenotype in Chronic Lymphocytic Leukemia.

Journal: International journal of molecular sciences
Published: October 31, 2024

The myth of a cancer-specific temperament: An analysis of affective temperament in cancer patients.

The myth of a cancer-specific temperament: An analysis of affective temperament in cancer patients.

Journal: Journal of psychosomatic research
Published: October 22, 2024

Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study.

Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study.

Journal: Blood advances
Published: September 23, 2024

Very low doses of rituximab in autoimmune hemolytic anemia-an open-label, phase II pilot trial.

Very low doses of rituximab in autoimmune hemolytic anemia-an open-label, phase II pilot trial.

Journal: Frontiers in medicine
Published: September 18, 2024
Showing 1-12 of 199

Last Updated: 09/26/2026